Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H1 2017 Summary Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Leukotriene A4 hydrolase (LTA4H) is an enzyme which converts leukotriene A4 to leukotriene B4 and acts as an aminopeptidase. LTB4 is a potent lipid chemoattractant involved in inflammation, immune responses, host defense against infection and PAF-induced shock. Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 3 and 1 respectively. Report covers products from therapy areas Cardiovascular, Respiratory, Dermatology and Hematological Disorders which include indications Pulmonary Arterial Hypertension, Acne Vulgaris, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Emphysema and Lymphedema. The latest report Leukotriene A 4 Hydrolase - Pipeline Review, H1 2017, outlays comprehensive information on... Research Beam Model: Research Beam Product ID: 1637921 3500 USD New
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H1 2017
 
 

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H1 2017

  • Category : Pharmaceuticals
  • Published On : June   2017
  • Pages : 40
  • Publisher : Global Markets Direct
 
 
 
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H1 2017

Summary

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Leukotriene A4 hydrolase (LTA4H) is an enzyme which converts leukotriene A4 to leukotriene B4 and acts as an aminopeptidase. LTB4 is a potent lipid chemoattractant involved in inflammation, immune responses, host defense against infection and PAF-induced shock.

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 3 and 1 respectively. Report covers products from therapy areas Cardiovascular, Respiratory, Dermatology and Hematological Disorders which include indications Pulmonary Arterial Hypertension, Acne Vulgaris, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Emphysema and Lymphedema.

The latest report Leukotriene A 4 Hydrolase - Pipeline Review, H1 2017, outlays comprehensive information on the Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6)
- The report reviews Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics and enlists all their major and minor projects
- The report assesses Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Overview
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Companies Involved in Therapeutics Development
Celtaxsys Inc
Johnson & Johnson
Nippon Kayaku Co Ltd
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Drug Profiles
acebilustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTX-3397 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDO-66 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-26993135 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Leukotriene B4 for Chronic Obstructive Pulmonary Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ubenimex - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Dormant Products
Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) - Product Development Milestones
Featured News & Press Releases
May 17, 2017: Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema
May 17, 2017: Celtaxsys Announces Full Enrollment of Its Landmark EMPIRE-CF Phase 2b Clinical Trial Assessing the Potential of Novel Anti-inflammatory Investigational Therapy, Oral Acebilustat, to Preserve Lung Function in CF Patients
May 15, 2017: Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
May 04, 2017: Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City
Jan 03, 2017: Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
Nov 03, 2016: Celtaxsys Announces Publication of Clinical Trial Results Demonstrating Novel Anti-inflammatory Medicine, Oral Acebilustat, Reduced Lung Inflammation Without Increased Risk of Immunosuppression, in CF Patients
Oct 28, 2016: Celtaxsys Announces Publication of Results Demonstrating Safety, Tolerability and PK/PD Profile of Novel Anti-inflammatory Medicine, Oral Acebilustat, in Phase 1 Clinical Trials including CF Patients
Jul 25, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema
Jul 18, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
May 03, 2016: Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis
Mar 28, 2016: Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency
Dec 15, 2015: Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering Bestatin (Ubenimex) for the Treatment of Pulmonary Arterial Hypertension
Dec 01, 2015: Celtaxsys to Present at 27th Annual Piper Jaffray Healthcare Conference
Nov 30, 2015: Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary
Oct 08, 2015: Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
DisclaimerList of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Celtaxsys Inc, H1 2017
Pipeline by Johnson & Johnson, H1 2017
Pipeline by Nippon Kayaku Co Ltd, H1 2017
Dormant Projects, H1 2017List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Top 10 Indications, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT